Signs Immunotherapy Is Working: What It Means, What to Expect and When to See a Specialist

Three weeks after her first infusion, a woman I once interviewed for this magazine described standing in her kitchen, hands on the counter, waiting to feel something. Chemotherapy had been loud: nausea, hair loss, the metallic taste. This was quiet. No signal at all. Was silence good news or bad?

That question sits at the heart of nearly every conversation about immunotherapy. Because the treatment works by recruiting your own immune cells rather than attacking the tumor directly, the early weeks can feel oddly uneventful. The real evidence arrives on a radiology screen, in a lab report, and in slow changes to daily life that are easy to miss unless you write them down.

This piece walks through what oncologists actually look for, why the first scan can mislead, which side effects mean something and which do not, and the handful of symptoms that should never wait for the next appointment.

Why can't you feel immunotherapy working?

Most medicines give you a bodily cue. A pain reliever dulls an ache within an hour; an antibiotic cools a fever in a day or two. Immunotherapy offers no such courtesy, and the reason is built into how it acts.

According to the National Cancer Institute, immunotherapy helps the immune system recognize and attack cancer cells rather than killing those cells with a chemical directly. The drug is a messenger, not a weapon. It removes a brake, flags a target, or trains a cell. The actual work is then done by T cells that must find the tumor, multiply, and begin dismantling it. That cascade unfolds over weeks, deep in tissue you cannot sense.

Compare it to hiring a security team for a building. On day one, nothing visible changes. Weeks later, the difference shows up in the incident log, not in how the lobby feels.

So the woman in the kitchen was asking a fair question with no immediate answer. Feeling nothing in the first month is neither reassurance nor warning. It is simply the expected texture of a treatment that works indirectly. The signals that matter are gathered by other means, and understanding those means is the best antidote to the anxiety of waiting.

What does immunotherapy actually do inside the body?

Cancer cells are, in a sense, escape artists. Many display molecules that tell approaching immune cells to stand down, or they simply look too much like healthy tissue to draw attention. Immunotherapy exists to break those disguises.

The National Cancer Institute groups the main approaches by mechanism:

• Immune checkpoint inhibitors block proteins that cancer uses to switch off T cells, releasing a natural brake.
• T-cell transfer therapy, including CAR T-cell therapy, removes a person’s own immune cells, equips them in a laboratory to target the cancer, and returns them in large numbers.
• Monoclonal antibodies mark cancer cells so the immune system can find them more easily.
• Treatment vaccines and immune system modulators broadly heighten the body’s response.

Notice what unites them: none shrinks a tumor by itself. Each relies on your immune cells to finish the job, and immune cells work on their own schedule. That is the single most useful idea for interpreting every sign discussed below. A response is a biological process ramping up, not a dose taking effect.

It also explains the side effects, which we will come to. An immune system freed from its brakes does not always confine itself to tumor tissue.

How long does immunotherapy take to show results?

Longer than most people expect, and longer than chemotherapy. That gap causes real distress, so it is worth being precise about what is known.

Cancer Research UK and the NHS both describe immunotherapy as a treatment whose effects build gradually, with progress checked by regular scans rather than by early symptom change. The NHS notes that treatment is typically given in cycles over months, with imaging used to see how the cancer is responding. Your oncologist will set the exact interval for your first restaging scan; for many regimens it falls a couple of months into treatment, though schedules differ by cancer type and by the specific therapy.

Why so slow? Immune cells have to be activated, expand in number, travel to every site of disease, and kill cells faster than the tumor can replace them. Each step takes days to weeks. A tumor does not simply switch off; it is worn down.

The practical consequence is that the first four to eight weeks usually generate no reliable information about benefit. Judging the treatment during that window, in either direction, is guesswork. The wiser posture is to note symptoms carefully, report anything new, and treat the first scheduled scan as the opening chapter rather than the verdict.

What do scans show when immunotherapy is working?

Imaging is the backbone of response assessment. Radiologists measure target lesions on CT, MRI, or PET scans and compare them with a baseline taken before treatment. The categories they use are standardized so that a report from one hospital means the same thing at another.

Scan finding	What it means	Usual interpretation
Complete response	No detectable disease on imaging	Strong sign of benefit; monitoring continues
Partial response	Measurable shrinkage of target lesions	Treatment is working
Stable disease	No meaningful growth or shrinkage	Often considered a good outcome with immunotherapy
Progression	Growth or new lesions	May be true progression or, early on, pseudoprogression

The National Cancer Institute explains that doctors use these scans, alongside physical exams and blood tests, to judge whether a treatment is helping. What the table cannot convey is nuance. A lesion may shrink while another holds steady. A PET scan may show reduced metabolic activity in a mass that has not yet changed size, which can be an early hint that cells inside are dying.

Ask to see the images with your oncologist if that helps you. Many people find that watching a shadow shrink across two scans makes the abstract concrete in a way no lab value can.

Can tumors look bigger before they shrink?

Yes, and this phenomenon, called pseudoprogression, is one of the most important things to understand before your first scan.

When immune cells flood into a tumor, the mass can swell. Inflammation, fluid, and the sheer volume of arriving T cells enlarge the lesion on imaging even as cancer cells within it are being destroyed. On a CT report, that looks like growth. Biologically, it may be the opposite.

The National Cancer Institute acknowledges this pattern in its discussion of checkpoint inhibitors: some tumors appear to grow before they shrink. Oncologists therefore interpret early scans cautiously. If you feel well and your blood work is reassuring, your team may choose to continue treatment and repeat imaging a few weeks later rather than change course on a single ambiguous result.

Pseudoprogression is not the majority experience, and true progression does occur. The distinction rests on the whole picture: how you feel, whether new symptoms have appeared, what tumor markers are doing, and how the next scan compares. Sometimes a biopsy settles the question by showing immune cells rather than proliferating cancer.

The takeaway is emotional as much as clinical. A first scan that reads “increase in size” is not automatically bad news. Give your oncologist room to explain what they think is happening.

Are side effects a sign immunotherapy is working?

This is the question people most want answered with a yes, and the honest response is: sometimes, partially, and never as proof.

Immune-related side effects happen because an activated immune system can attack healthy tissue as well as tumor. The National Cancer Institute lists common effects including skin rash, itching, fatigue, diarrhea, and inflammation of the thyroid, liver, lungs, or bowel. Researchers have observed that people who develop certain immune-related effects, particularly skin changes or thyroid inflammation, sometimes show better responses, which makes biological sense: the immune system is clearly awake.

Two cautions keep that observation from becoming a rule. First, plenty of people respond beautifully with almost no side effects at all. A quiet body does not mean a quiet immune response against the tumor. Second, severe side effects are dangerous in their own right, and no one should welcome them as evidence of benefit. An inflamed colon or lung needs prompt treatment regardless of what the tumor is doing.

Think of side effects as a smoke signal from the immune system rather than a report card on the cancer. They tell you the engine is running. Only the scan tells you where the car is going.

What physical changes might you notice at home?

Between scans, the body does offer clues, though they are gentle and easily missed. The most telling are improvements in whatever the cancer was causing before treatment.

If a tumor was pressing on a nerve, pain may ease. A lung lesion that provoked coughing or breathlessness may quiet down, so that the stairs feel shorter. An enlarged lymph node under the jaw or in the armpit may soften or shrink to the touch. Appetite can return; the belt may go back a notch as unintended weight loss stops. Night sweats linked to lymphoma may fade.

The NHS encourages people on cancer treatment to keep a record of symptoms and report changes, partly because trends are more informative than any single day. A pain score that drifts from seven to four over six weeks says more than one good afternoon.

Fatigue is the exception. Tiredness is both a common side effect and a symptom of cancer itself, so it rarely helps in either direction.

One caution: improvement in how you feel is encouraging but not conclusive. Steroids or pain medicines can ease symptoms independently of tumor response. Bring your notes to each visit and let your team weigh them alongside the imaging.

Do blood tests show immunotherapy is working?

For some cancers, yes, in a limited but useful way. Certain tumors release proteins or other substances into the blood at levels that track with the amount of disease. MedlinePlus describes these tumor markers as substances that can help monitor how a cancer responds to treatment when interpreted alongside other tests.

Where a marker exists for your cancer, a falling level across several draws is a reassuring sign. A rising level prompts closer attention, though markers can bump upward transiently, including during the same inflammatory burst that causes pseudoprogression. Your oncologist will look at the direction of travel over time rather than any single value.

Blood tests also serve a second purpose that has nothing to do with the tumor: safety. Liver enzymes, thyroid hormones, kidney function, blood sugar, and blood counts are checked regularly because immune-related side effects often show up in the lab before you feel them. A quietly rising liver enzyme may be the first hint of immune hepatitis; a shifting thyroid value may explain new fatigue.

Not every cancer has a reliable marker, and none replaces imaging. Consider blood work a supporting witness. It corroborates the story told by the scan and, just as importantly, keeps the treatment itself safe enough to continue.

What does 'stable disease' mean, and is it good news?

Few phrases in an oncology report land as ambiguously as “stable disease.” It sounds like a shrug. With immunotherapy, it often deserves a quiet cheer.

Stable means the target lesions have neither grown nor shrunk beyond a defined threshold since the last comparison. For a cancer that was expanding before treatment, halting that expansion is itself a change in trajectory. The immune system may be holding the tumor in check, killing cells roughly as fast as they divide.

The National Cancer Institute notes that immunotherapy responses can take time to develop and can persist. In practice, that means stable disease at an early scan sometimes evolves into partial response later, as the immune assault gathers momentum. Oncologists commonly continue treatment through stable disease provided the person is tolerating it well.

Stable disease is also compatible with feeling better. If the tumor is no longer growing, the symptoms it drives usually stop worsening and may ease.

None of this means stability is guaranteed to improve, and your team will keep watching. But if your report says stable, resist the instinct to read it as failure. Ask your oncologist how it compares with your pre-treatment scan and what they expect from the next one.

Why are some immunotherapy responses so long-lasting?

One of the features that first drew attention to immunotherapy was durability. Chemotherapy stops working when the drug leaves the body; an immune system that has learned to recognize a tumor may keep patrolling long after the last infusion.

The mechanism is memory. When T cells are activated against a target, a subset become memory cells that can persist for years and reactivate if that target reappears. The same principle protects you from a virus you met decades ago. The National Cancer Institute observes that immunotherapy may continue working for a period after treatment ends, and that some responses are long-lasting.

This has a practical implication for how oncologists judge success. A response that holds steady over repeated scans, especially after treatment is paused, is itself a strong sign. Stability across a year can mean more than a dramatic early shrinkage that later reverses.

It also reframes what “working” means. For some people the goal is not disappearance of every lesion but a long, quiet truce in which the cancer is contained and life goes on largely as before. Whether that applies to your situation depends on cancer type and many individual factors, which is a conversation for your prescribing clinician, not a magazine.

What if immunotherapy isn't working?

Not every cancer responds, and not every response lasts. Recognizing that early matters as much as recognizing success, because it opens the door to other options.

Signs that raise concern include clear growth of existing lesions on two consecutive scans, new lesions appearing in places that were previously clear, tumor markers climbing steadily, and worsening of the symptoms the cancer caused before treatment. When several of these line up, and enough time has passed to rule out pseudoprogression, your oncologist will likely discuss a change in plan.

Some tumors never respond because they lack the features the immune system needs to see them. Others respond and then adapt, developing new ways to hide. Researchers continue to study why, and the National Cancer Institute notes that combining immunotherapy with other treatments is an active area of investigation.

Hearing that a treatment has not worked is painful, and it is reasonable to grieve that. It is also worth remembering that the decision to switch is usually made from a position of knowledge: your team now understands how this particular cancer behaves, which informs the next step. Ask what alternatives exist, whether a clinical trial is appropriate, and how quickly a change should happen.

When should you see a specialist or seek urgent care?

Immunotherapy side effects can arise at any point, including months after treatment ends, and the National Cancer Institute stresses that they are easiest to manage when caught early. You are the first line of detection, so err on the side of calling.

Contact your oncology team the same day for:

• Diarrhea that is new, frequent, or contains blood or mucus, or severe abdominal pain
• New or worsening shortness of breath, cough, or chest pain
• Yellowing of the skin or eyes, dark urine, or pain under the right ribs
• Severe headache, vision changes, or extreme thirst and frequent urination
• Fever, chills, or signs of infection
• Widespread rash, blistering, or mouth sores
• Sudden weakness, numbness, confusion, or a racing heartbeat

These can signal immune inflammation of the bowel, lungs, liver, pituitary or other glands, skin, or nerves, all of which are treatable when addressed promptly. Do not wait for a scheduled visit, and do not assume a symptom is “just the treatment working.”

Separately, see your specialist sooner than planned if the symptoms your cancer caused are clearly worsening, if you notice a new lump, or if pain is escalating. Between the two, the rule is simple: anything sudden, severe, or unfamiliar earns a phone call, and calling too often is a far smaller problem than calling too late.

How can you track your progress between appointments?

Waiting for scans is easier when you have your own data. A simple notebook or phone note, updated every few days, turns vague worry into something you can hand to your oncologist.

Record a daily energy score, a pain score, sleep quality, appetite, and any new symptom with the date it began. Note the size of any lump you can feel, measured against a coin or fingertip so comparisons are consistent. Track weight weekly on the same scale. The NHS recommends keeping a record of side effects so your care team can spot patterns and adjust support.

Then look at trends, not days. A bad Tuesday means little; three weeks of steadier energy means something. Bring the log to every visit and ask your oncologist how it lines up with the imaging and blood work.

Two things this log should not become: a substitute for calling about red-flag symptoms, and a source of self-diagnosis. Its purpose is to make you a sharper observer and a better partner in your own care.

The woman in the kitchen eventually stopped waiting to feel the treatment work. She started counting the stairs she could climb without stopping instead. By her second scan, she already knew what it would say.

Frequently asked questions

How soon can you tell if immunotherapy is working?

Usually not before the first restaging scan, which oncologists typically schedule a couple of months into treatment, with the exact timing depending on cancer type and regimen. Immunotherapy works by activating immune cells that must multiply and reach the tumor, a process that unfolds over weeks. Early symptom changes can hint at benefit, but imaging and blood work provide the reliable answer.

Does feeling no side effects mean immunotherapy isn't working?

No. Many people respond well to immunotherapy with few or no noticeable side effects. Side effects reflect the immune system acting on healthy tissue, which is separate from whether it is attacking the tumor. Some studies have linked certain immune-related effects with better responses, but the absence of side effects is not evidence of failure, and response is confirmed by scans.

Can a tumor grow before it shrinks on immunotherapy?

Yes. This is called pseudoprogression. When immune cells infiltrate a tumor, inflammation and cellular influx can enlarge it on imaging even while cancer cells are dying. Oncologists therefore interpret early scans cautiously, often continuing treatment and repeating imaging if you feel well. True progression does occur, so the whole picture, including symptoms and blood markers, guides the decision.

Is stable disease a good result with immunotherapy?

Often, yes. Stable disease means the cancer has stopped growing beyond a defined threshold, which for a previously expanding tumor is a real change in course. Because immunotherapy responses build gradually, stable disease at an early scan sometimes becomes shrinkage later. Oncologists commonly continue treatment through stability when it is well tolerated and the person feels no worse.

What symptoms suggest immunotherapy is working?

Improvement in the problems the cancer caused before treatment is the most useful sign: less pain, easier breathing, a smaller lump, returning appetite, or fading night sweats. These changes tend to appear gradually over weeks. Keep a written log and look at trends. Symptom improvement is encouraging but not conclusive, because pain medicines or steroids can also ease symptoms.

Do blood tests show whether immunotherapy is working?

For some cancers, tumor-marker blood tests fall as disease responds, and a downward trend across several draws is reassuring. Not every cancer has a reliable marker, and markers can fluctuate temporarily. Blood tests are also essential for safety, detecting immune-related inflammation of the liver, thyroid, or other organs before symptoms appear. They support imaging rather than replace it.

How long does immunotherapy keep working after treatment stops?

It can continue for an extended period, because immune cells trained against a tumor may persist as memory cells and keep patrolling. The National Cancer Institute notes that some immunotherapy responses are long-lasting and can continue after treatment ends. How long this applies to any individual varies widely with cancer type and other factors, which your oncologist can discuss.

What are the red-flag side effects of immunotherapy?

Call your oncology team the same day for new or bloody diarrhea, severe abdominal pain, shortness of breath or chest pain, yellowing skin or eyes, severe headache or vision changes, fever, widespread rash or blistering, sudden weakness, or confusion. These can signal immune inflammation of the bowel, lungs, liver, glands, or nerves, which is treatable when caught early. Do not wait for a scheduled visit.

Why does immunotherapy take longer than chemotherapy to show results?

Chemotherapy damages dividing cells directly, so its effect begins as soon as the drug circulates. Immunotherapy instead removes brakes on or redirects immune cells, which must then activate, expand in number, travel to every tumor site, and outpace cancer growth. Each step takes days to weeks, so measurable change typically appears later and builds over successive scans.

What happens if immunotherapy doesn't work?

Your oncologist will look for growth on consecutive scans, new lesions, rising markers, and worsening symptoms, and will rule out pseudoprogression before concluding the treatment has failed. If so, options may include a different immunotherapy, other cancer treatments, combinations, or a clinical trial. Ask what alternatives exist and how quickly a change should happen; the decision rests with your prescribing clinician.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.